Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer

NCT06490328 is registered in ClinicalTrials.gov with Dongkook Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06490328
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06490328 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Single-group, Open-label Study to Evaluate the Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer
Lead sponsor
Dongkook Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
May 30, 2024
Completion date
March 9, 2026
Enrollment
161 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

advanced prostate cancer